Acute leukemia arising after radioiodine treatment for thyroid cancer by Marine Gilabert, Thomas Prebet

Get full text

Insights into novel emerging epigenetic drugs in myeloid malignancies by Namrata S. Chandhok, Thomas Prebet

Get full text

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system by Thomas Prebet, Pierre Fenaux, Norbert Vey

Get full text

Biofuels Barrier Properties of Polyamide 6 and High Density Polyethylene by Fillot L.-A., Ghiringhelli S., Prebet C., Rossi S.

Get full text

Emerging treatment options for patients with high-risk myelodysplastic syndrome by Jan Philipp Bewersdorf, Hetty Carraway, Thomas Prebet

Get full text

A simplified, 96-well–adapted, ATP luminescence–based motility assay by Audrey Restouin, Sandra Aresta, Thomas Prébet, Jean-Paul Borg, Ali Badache, Yves Collette

Get full text

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure by Thomas Prébet, Sylvain Thepot, Steven D. Gore, François Dreyfus, Pierre Fenaux, Norbert Vey

Get full text

Epigenetics in Cancer: A Hematological Perspective. by Maximilian Stahl, Nathan Kohrman, Steven D Gore, Tae Kon Kim, Amer M Zeidan, Thomas Prebet

Get full text

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysi... by Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prebet

Get full text

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. by Santini, V, Prebet, T, Fenaux, P, Gattermann, N, Nilsson, L, Pfeilstöcker, M, Vyas, P, List, A

Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity by Anne-Sophie eChretien, Aude eLe Roy, Norbert eVey, Norbert eVey, Thomas ePrebet, Thomas ePrebet, Didier eBlaise, Didier eBlaise, Cyril eFauriat, Daniel eOlive, Daniel eOlive

Get full text

Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases by Philippa Li, Giulia Biancon, Timil Patel, Zenggang Pan, Shalin Kothari, Stephanie Halene, Thomas Prebet, Mina L. Xu

Get full text

P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGR... by A. H. Wei, H. E. Carraway, L. Taningco, E. Laille, J. Gong, T. Prebet, D. Lopes de Menezes, F. Ravandi

Get full text

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia by Thomas Prebet, Sarah Bertoli, Jacques Delaunay, Arnaud Pigneux, Eric Delabesse, Marie Joelle Mozziconacci, Audrey Bidet, Christian Recher, Norbert Vey

Get full text

Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia by Risueño, A, See, WL, Prebet, T, DiNardo, C, Döhner, H, Stein, EM, Fathi, AT, Vyas, P, Quek, L, Gandhi, A, Hasan, M

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON by E. N. Oliva, C. Chen, S. N. Rahim, B. Seuro, A. Vasconcelos, L. Gaugler, B. Skikne, T. Prebet, H. Cameron, C. Beach, G. Thompson

Get full text

P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA by A. M. Zeidan, D. A. Pollyea, U. Borate, A. Vasconcelos, R. Potluri, D. Rotter, Z. Kiendrebeogo, L. Gaugler, G. Bonifacio, T. Prebet, C. Chen

Get full text

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES by Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Takahiro Suzuki, Mikkael Sekeres, Jun He, Ronit Barkalifa, Carlos Vigil, Thomas Prebet, Rami S. Komrokji, Aristoteles Giagounidis

Get full text

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML by Risueño, A, See, WL, Bluemmert, I, de Botton, S, DiNardo, CD, Fathi, AT, Schuh, AC, Montesinos, P, Vyas, P, Prebet, T, Gandhi, A, Hasan, M

P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA by Shaun Fleming, Gail Roboz, Amir T. Fathi, Tian Y. Zhang, Andrew Wei, Hetty Carraway, Leanne Holes, Erica Petrlik, Thomas Prebet, Daniel Lopes De Menezes, Iryna Bluemmert, Hao Sun, Farhad Ravandi

Get full text